Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VH4004280 Formulation A · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1 - Regimen A | EXPERIMENTAL | VH4004280 Formulation A tablet administered in fed conditions. |
| Part 1 - Regimen B | EXPERIMENTAL | VH4004280 Formulation B tablet administered in fed conditions. |
| Part 1 - Regimen C | EXPERIMENTAL | VH4004280 Formulation C tablet administered in fed conditions. |
| Part 1 - Optional Regimen D | EXPERIMENTAL | VH4004280 Formulation D tablet administered in fed conditions. |
| Part 1 - Optional Regimen E | EXPERIMENTAL | VH4004280 Formulation E tablet administered in fed conditions. |
| Part 2 - Regimen A | EXPERIMENTAL | VH4004280 Formulation A tablet administered in fasted conditions. |
| Part 2- Optional Regimen 1 | EXPERIMENTAL | VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions. |
| Part 2- Optional Regimen 2 | EXPERIMENTAL | VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions. |
| Part 2- Optional Regimen 3 | EXPERIMENTAL | VH4004280 Formulation B, C, D, or E tablet administered in fasted conditions. |
| Part 3 - Optional Regimen 1 | EXPERIMENTAL | VH4004280 Formulation A, B, C or D tablet administered in lower fat conditions. |
| Part 3- Optional Regimen 2 | EXPERIMENTAL | VH4004280 Formulation A, B, C or D tablet administered in lower fat conditions. |
| Part 3 - Optional Regimen 3 | EXPERIMENTAL | VH4004280 Formulation A, B, C or D tablet administered in lower fat conditions. |
| Part 3 - Optional Regimen 4 | EXPERIMENTAL | VH4004280 Formulation A, B, C or D tablet administered in lower fat conditions. |
| Name | Type | Description |
|---|---|---|
| VH4004280 Formulation A | DRUG | Oral administration of VH4004280 Formulation A in fasted or fed conditions. |
| VH4004280 Formulation B | DRUG | Oral administration of VH4004280 Formulation B in fasted or fed conditions. |
| VH4004280 Formulation C | DRUG | Oral administration of VH4004280 Formulation C in fasted or fed conditions. |
| VH4004280 Formulation D | DRUG | Oral administration of VH4004280 Formulation D in fasted or fed conditions. |
| VH4004280 Formulation E | DRUG | Oral administration of VH4004280 Formulation E in fasted or fed conditions. |
Inclusion Criteria: 1. Participants must be 18 to 55years of age. 2. Participants who are overtly healthy. 3. Negative (Severe Acute Respiratory Syndrome Coronavirus 2) SARs-CoV-2 test prior to dosing. 4. Has body mass index (BMI) within the range 19-32 (kg/m2). 5. Participants male at birth must u...
Top 20 of 28 competitors
VH4004280 Formulation A is an investigational small molecule being developed for HIV Infections. It is currently in Phase 1 clinical development and is not approved by regulatory authorities. The drug is being studied in healthy volunteers to evaluate its pharmacokinetic properties.
VH4004280 Formulation A is an oral capsid inhibitor, meaning it targets the HIV capsid protein. By inhibiting the capsid, the drug aims to disrupt multiple steps of the HIV replication cycle. This mechanism is being investigated as a potential treatment for HIV Infections.
VH4004280 Formulation A is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetics in healthy participants.
VH4004280 Formulation A is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research for HIV Infections.
VH4004280 Formulation A has one completed clinical trial, NCT06168318. This Phase 1 study investigated the relative bioavailability and food effect of an oral capsid inhibitor tablet formulation compared with other oral tablet formulations in healthy participants. The trial enrolled 46 participants in the United Kingdom.
VH4004280 Formulation A is a specific tablet formulation of an oral capsid inhibitor being studied for HIV Infections. The clinical trial NCT06168318 compared this formulation with other oral tablet formulations of the same drug to assess relative bioavailability and food effects.